{"gene":"NKX3-1","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":1997,"finding":"NKX3.1 encodes a 38 kDa homeoprotein with DNA binding properties similar to other Nkx family members; it is expressed in a prostate-specific and androgen-regulated manner, with castration significantly reducing expression, establishing androgen dependence for maintenance.","method":"RNase protection analysis, in situ hybridization, castration experiments","journal":"Developmental dynamics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, foundational characterization paper, highly cited","pmids":["9142502"],"is_preprint":false},{"year":1997,"finding":"NKX3.1 mRNA is induced 6–7 fold by androgens in LNCaP cells within 12 hours, at the level of transcription and independent of de novo protein synthesis, establishing androgen receptor-mediated transcriptional regulation.","method":"Differential display PCR, Northern blot, androgen stimulation, transcription inhibition assays","journal":"The Prostate","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, replicated across studies","pmids":["9537602"],"is_preprint":false},{"year":1999,"finding":"Nkx3.1 null mutation (targeted gene disruption) results in defects in prostate ductal morphogenesis, secretory protein production, and progressive prostatic epithelial hyperplasia and dysplasia; haploinsufficiency is sufficient to cause these phenotypes, establishing Nkx3.1 as a prostate tumor suppressor with growth-suppressive roles in prostatic epithelium.","method":"Targeted gene disruption, histopathology, tissue recombinants","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined phenotypic readout, replicated by multiple labs, >500 citations","pmids":["10215624"],"is_preprint":false},{"year":2000,"finding":"NKX3.1 binds a novel TAAGTA consensus DNA sequence (distinct from other NK family members) with ~20 nM affinity, and functions as a transcriptional repressor from this site in reporter assays.","method":"Binding site selection assay, EMSA, luciferase reporter assay, competitive gel shift with mutated binding sites","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution with mutagenesis and functional validation","pmids":["10871372"],"is_preprint":false},{"year":2000,"finding":"Targeted disruption of Nkx3.1 causes defective branching morphogenesis and epithelial hyperplasia in prostate and palatine glands, with no effects on sclerotome, blood vessels, kidney, or brain, demonstrating organ-specific roles.","method":"Targeted gene disruption, histological analysis","journal":"Developmental dynamics","confidence":"High","confidence_rationale":"Tier 2 — clean KO with specific phenotypic readout, replicated findings","pmids":["11002344"],"is_preprint":false},{"year":2002,"finding":"Loss of Nkx3.1 cooperates with loss of Pten in prostate cancer progression, with cooperativity mediated by synergistic activation of Akt (PKB), establishing Nkx3.1 within the PTEN-AKT signaling pathway.","method":"Compound mutant mouse models, Western blot for phospho-Akt, histopathology","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with molecular readout, highly cited","pmids":["11854455"],"is_preprint":false},{"year":2002,"finding":"Conditional Cre/loxP-mediated deletion of Nkx3.1 in adult mouse prostate (one or both alleles) leads to PIN-like lesions; PIN foci in single-allele conditional knockouts lose expression of the wild-type allele, supporting haploinsufficiency and tumor suppressor role.","method":"Conditional Cre/loxP recombination, immunohistochemistry for Ki-67/E-cadherin/cytokeratins","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined cellular phenotype, mechanistically informative","pmids":["11839815"],"is_preprint":false},{"year":2002,"finding":"Nkx3.1 displays growth-suppressing activities in cell culture and aged Nkx3.1 mutant mice develop PIN-like histopathological lesions that undergo progressively severe alterations after serial transplantation in nude mice.","method":"Cell culture growth assays, histopathology, tissue recombination/serial transplantation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with defined cellular and in vivo phenotype","pmids":["12036903"],"is_preprint":false},{"year":2003,"finding":"Nkx3.1 haploinsufficiency extends the proliferative stage of regenerating luminal cells; the number of Nkx3.1 alleles determines the probability of stochastic activation or inactivation of dosage-sensitive target genes, as revealed by microarray analysis.","method":"Mouse model analysis, microarray gene expression profiling, histopathology","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — multiple methods in vivo and in vitro establishing mechanistic principle","pmids":["12676585"],"is_preprint":false},{"year":2005,"finding":"Loss-of-function of Nkx3.1 leads to deregulated expression of antioxidant and prooxidant enzymes (GPx2, GPx3, Prdx6, Qscn6) and increased oxidative DNA damage (8-OHdG), linking Nkx3.1 to protection of prostatic epithelium against oxidative stress.","method":"Gene expression profiling, immunohistochemistry for 8-OHdG, Nkx3.1 null and compound mutant mice","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function mouse model with molecular mechanistic readout","pmids":["16061659"],"is_preprint":false},{"year":2006,"finding":"NKX3.1 associates with HDAC1, leading to increased p53 acetylation and p53 half-life via MDM2-dependent mechanisms; NKX3.1 also negatively modulates AR transcription and blocks AKT activation in PTEN-null prostate epithelium.","method":"Co-immunoprecipitation, in vivo restoration of Nkx3.1 in Pten-null mice, proliferation/apoptosis assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus in vivo rescue experiment, multiple mechanistic endpoints","pmids":["16697957"],"is_preprint":false},{"year":2006,"finding":"NKX3.1 is regulated by protein kinase CK2: CK2 phosphorylates NKX3.1 on Thr89 and Thr93 in vitro, and CK2 activity is required for NKX3.1 stability in cells; specifically, free CK2α' (not holoenzyme) phosphorylates NKX3.1, establishing CK2α' as a regulator of NKX3.1 stability.","method":"In vitro kinase assay with mass spectrometry, CK2 inhibitors, siRNA knockdown, in-gel kinase assay, mutational analysis (T89A/T93A)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with MS identification of phosphosites plus mutagenesis and cellular validation","pmids":["16581776"],"is_preprint":false},{"year":2006,"finding":"A germline T164A mutation in the NKX3.1 homeodomain (found in a hereditary prostate cancer family) alters homeodomain stability and decreases DNA-binding activity, as determined by NMR solution structure and circular dichroism.","method":"NMR spectroscopy, circular dichroism, DNA binding assays, family genetic analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — structural (NMR) plus functional validation","pmids":["16397218"],"is_preprint":false},{"year":2006,"finding":"NKX3.1 physically interacts with serum response factor (SRF) via three N-terminal motifs (TN/EH-1 motif residues 29–35, SI motif residues 99–105, and acidic domain residues 88–96) and acts as a transcriptional co-activator of the smooth muscle gamma-actin promoter.","method":"NMR spectroscopy, targeted mutagenesis, SMGA reporter assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — NMR structure determination plus mutagenesis with functional reporter validation","pmids":["16814806"],"is_preprint":false},{"year":2007,"finding":"NKX3.1 directly binds topoisomerase I (Topo I) via its homeodomain (with Topo I core-linker domain junction), enhances Topo I-DNA complex formation and Topo I DNA cleavage activity; endogenous NKX3.1 and Topo I co-immunoprecipitate and co-localize in the nucleus, co-migrating to DNA damage sites after genotoxic stress. Topo I activity in prostates of Nkx3.1 null mice is reduced compared to wild-type.","method":"Affinity column pulldown, co-IP from LNCaP cells, in vitro Topo I activity assays, co-localization by immunofluorescence, genetically engineered mice","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical reconstitution plus in vivo genetic validation and cellular co-localization","pmids":["17234752"],"is_preprint":false},{"year":2007,"finding":"The NKX3.1 haploinsufficiency phenotype is linked to differential histone H3/H4 acetylation states of dosage-sensitive target genes; NKX3.1 associates with and recruits the histone acetyltransferase p300/PCAF (p300/CBP-associated factor) to chromatin to regulate target gene expression.","method":"ChIP for histone acetylation, HDAC inhibitor (TSA) rescue, co-immunoprecipitation for p300/PCAF","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus ChIP with pharmacological rescue, mechanistically coherent","pmids":["17602165"],"is_preprint":false},{"year":2007,"finding":"TOPORS, an E3 ubiquitin ligase, interacts with NKX3.1, ubiquitinates it in vitro and in vivo, and overexpression of TOPORS leads to NKX3.1 proteasomal degradation; siRNA knockdown of TOPORS increases NKX3.1 steady-state level and half-life.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, siRNA knockdown, protein half-life assay","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro ubiquitination assay plus cellular gain/loss-of-function experiments","pmids":["18077445"],"is_preprint":false},{"year":2008,"finding":"Inflammatory cytokines TNF-α and IL-1β accelerate NKX3.1 protein loss by inducing rapid ubiquitination and proteasomal degradation; TNF-α acts via phosphorylation of C-terminal serine 196 (mutation S196A abrogates this); steady-state NKX3.1 turnover is controlled by serine 185; serine 195 has a modulating role on both pathways.","method":"Site-directed mutagenesis (S196A, S185A, S195A), cytokine treatment, ubiquitination assays, protein half-life measurements","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis mapping of phosphosites with functional ubiquitination and degradation assays","pmids":["18757402"],"is_preprint":false},{"year":2008,"finding":"NKX3.1 physically interacts with MYOCD (myocardin) and is required for full MYOCD-dependent transactivation of the ACTG2 promoter through an NKX3.1 binding site adjacent to CArG2; functional association demonstrated by co-IP, GST pulldown, and luciferase assays.","method":"Co-immunoprecipitation, GST pulldown, luciferase reporter assay, gel shift assay","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical interaction (Co-IP + GST pulldown) plus functional reporter assay","pmids":["19797053"],"is_preprint":false},{"year":2009,"finding":"NKX3.1 activates expression of IGFBP-3 mRNA and protein ~10-fold; this activation attenuates IGF-I-induced phosphorylation of IGF-IR, IRS-1, PI3K, and AKT; siRNA knockdown of IGFBP-3 partially reverses NKX3.1's growth-suppressive effects, establishing IGFBP-3 as a downstream mediator of NKX3.1 tumor suppression.","method":"Expression microarray, stable transfection, siRNA knockdown, Western blot for signaling intermediates, proliferation assays, Nkx3.1 gene-targeted mice","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in vitro and in vivo","pmids":["19258508"],"is_preprint":false},{"year":2010,"finding":"NKX3.1 localizes to sites of DNA damage, enhances ATM autophosphorylation at Ser1981, activates ATR (via CHK1 phosphorylation), and affects recruitment of phospho-ATM and H2AX phosphorylation at DNA damage foci; an inherited DNA-binding mutant is devoid of ATM activation and γH2AX co-localization.","method":"Immunofluorescence co-localization, siRNA knockdown of NKX3.1 in LNCaP, overexpression in PC-3, colony formation after DNA damage, ATM kinase activation assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods linking NKX3.1 to DNA damage response machinery with mutant validation","pmids":["20395202"],"is_preprint":false},{"year":2010,"finding":"NKX3.1 co-localizes genome-wide with the androgen receptor (AR) as shown by ChIP-seq; NKX3.1 and AR directly regulate each other in a feed-forward loop; NKX3.1 collaborates with AR and FoxA1 to regulate a gene network including RAB3B, a RAB GTPase that promotes prostate cancer cell survival.","method":"ChIP-seq, luciferase reporter assay, siRNA knockdown, gene expression profiling","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq plus functional knockdown with defined transcriptional network","pmids":["22083957"],"is_preprint":false},{"year":2010,"finding":"NKX3.1 is a direct transcriptional target of the TAL1-LMO-Ldb1 complex (recruited by GATA-3 to the NKX3.1 promoter) in T-ALL cells; NKX3.1 activation is associated with suppression of HP1-α and chromatin opening at its promoter; NKX3.1 is required for T-ALL proliferation and directly regulates miR-17-92.","method":"ChIP, siRNA/shRNA knockdown, reporter assays, in vivo leukemia engraftment","journal":"Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct complex recruitment plus functional knockdown with proliferation and in vivo engraftment readouts","pmids":["20855495"],"is_preprint":false},{"year":2010,"finding":"ERG and ESE3 ETS factors control Nkx3.1 expression both directly (binding to NKX3.1 gene regulatory elements) and indirectly through regulation of EZH2 (Polycomb Group protein), which epigenetically silences Nkx3.1.","method":"ChIP, reporter assay, siRNA knockdown, gene expression profiling","journal":"PLoS One","confidence":"High","confidence_rationale":"Tier 2 — ChIP with functional reporter assays and siRNA knockdown across multiple cell lines","pmids":["20479932"],"is_preprint":false},{"year":2012,"finding":"Nkx3.1 and Myc directly bind and crossregulate shared target genes in prostate epithelial cells; Nkx3.1 can oppose Myc transcriptional activity; loss of Nkx3.1 cooperates with Myc overexpression to promote prostate cancer in transgenic mice.","method":"ChIP-seq, gene expression profiling, reporter assays, transgenic mice with compound mutations","journal":"Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq plus in vivo genetic cooperativity model","pmids":["22484818"],"is_preprint":false},{"year":2013,"finding":"NKX3.1 undergoes phosphorylation at tyrosine 222 within minutes of DNA damage, which is required for functional interaction with ATM kinase N-terminal domain; NKX3.1 binding to ATM accelerates ATM activation, hastens γH2AX formation, and enhances ATM kinase activity in a DNA-damage-independent manner; ATM then phosphorylates NKX3.1, leading to its ubiquitination and degradation.","method":"Co-immunoprecipitation, in vitro ATM kinase assay, phospho-mutant analysis, γH2AX kinetics assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay plus Co-IP with phospho-mutant validation","pmids":["23890999"],"is_preprint":false},{"year":2013,"finding":"NKX3.1 homeodomain binds the topoisomerase I core-linker domain junction; NKX3.1 inhibits the DNA-resolving activity of reconstituted Topo I in vitro while enhancing full-length Topo I activity; Topo I knockdown blocks NKX3.1's effect on clonogenicity after DNA damage.","method":"In vitro Topo I activity assay with reconstituted enzyme fragments, domain mapping, siRNA knockdown, clonogenic survival assay","journal":"Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution with domain mapping and cellular validation","pmids":["23557481"],"is_preprint":false},{"year":2013,"finding":"NKX3.1 represses TWIST1 expression by directly binding to the TWIST1 promoter; NKX3.1 overexpression reduces TWIST1 promoter reporter activity, and NKX3.1 siRNA upregulates endogenous TWIST1, establishing TWIST1 as a direct NKX3.1 target gene involved in EMT.","method":"ChIP, luciferase reporter assay, siRNA knockdown, RT-PCR","journal":"Cancer cell international","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus reporter assay and gain/loss-of-function with multiple methods","pmids":["23368843"],"is_preprint":false},{"year":2013,"finding":"NKX3.1 represses RAMP1 expression by directly binding multiple sites in the RAMP1 locus; loss of NKX3.1 in knockout mice elevates RAMP1, and knockdown of RAMP1 in prostate cancer cells decreases proliferation, tumorigenicity, and MEK-ERK signaling.","method":"ChIP-seq, gene expression profiling, shRNA knockdown, xenograft tumor model","journal":"American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq with in vivo mouse genetics and functional cellular/xenograft validation","pmids":["23867798"],"is_preprint":false},{"year":2013,"finding":"Pim-1 kinase stabilizes NKX3.1 protein by phosphorylating it at Thr89, Ser185, Ser186, Ser195, and Ser196; Pim-1-mediated stabilization requires phosphorylation at Ser185, Ser186, and N-terminal PEST domain and Lys182, protecting NKX3.1 from proteasomal degradation.","method":"Mass spectrometry identification of phosphosites, Pim-1 inhibitor treatment, mutational analysis, protein half-life assay, proteasome inhibitor rescue","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1 — MS-identified phosphosites with mutagenesis and pharmacological validation","pmids":["23129228"],"is_preprint":false},{"year":2015,"finding":"DYRK1B kinase directly phosphorylates NKX3.1 at serine 185 (the residue critical for steady-state turnover) via its kinase domain interaction with NKX3.1; DYRK1B inhibitors prolong NKX3.1 half-life.","method":"siRNA library screen, in vitro kinase assay, co-IP (DYRK1B kinase domain), protein half-life assay, small-molecule inhibition","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with substrate identification and pharmacological validation","pmids":["25777618"],"is_preprint":false},{"year":2015,"finding":"NKX3.1 binds at the ERG gene breakpoint, inhibits juxtaposition of TMPRSS2 and ERG gene loci, suppresses their recombination, and promotes homology-directed DNA repair; loss of NKX3.1 favors error-prone non-homologous end-joining at the ERG breakpoint.","method":"ChIP at ERG breakpoint, FISH for loci juxtaposition, DNA repair pathway factor recruitment assays, human tissue correlation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus mechanistic DNA repair pathway analysis with clinical correlation","pmids":["25977336"],"is_preprint":false},{"year":2016,"finding":"NKX3.1 gain-of-function in seminal vesicle epithelium is sufficient to respecify it toward a prostate fate in renal grafts; this activity requires interaction of NKX3.1 with the G9a histone methyltransferase via the homeodomain, and is mediated by activation of UTY (KDM6c), identifying an NKX3.1-G9a-UTY transcriptional regulatory network essential for prostate differentiation.","method":"In vivo renal graft respecification, Co-IP (NKX3.1-G9a interaction), gene expression profiling, loss-of-function mouse models","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo gain-of-function respecification plus Co-IP and molecular network characterization","pmids":["27339988"],"is_preprint":false},{"year":2018,"finding":"NKX3-1 functions downstream of the IL-6-STAT3 signaling pathway to activate endogenous OCT4 expression during reprogramming; NKX3-1 can substitute for exogenous OCT4 to generate fully pluripotent iPSCs from both mouse and human fibroblasts.","method":"Heterokaryon reprogramming system, siRNA knockdown, STAT3 pathway inhibition, iPSC generation and characterization","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (IL-6-STAT3-NKX3-1-OCT4) plus functional iPSC generation with knockdown rescue","pmids":["30013107"],"is_preprint":false},{"year":2019,"finding":"PTEN functions as a phosphatase of NKX3.1, opposing DYRK1B-mediated phosphorylation at Ser185 and prolonging NKX3.1 half-life; PTEN and NKX3.1 interact primarily in the nucleus (nuclear PTEN localization is required); loss of PTEN in gene-targeted mice leads to rapid decrease in Nkx3.1 protein without affecting Nkx3.1 mRNA.","method":"Co-IP (PTEN-NKX3.1), mutational analysis (nuclear localization signal of PTEN), protein half-life assay, gene-targeted mice, Western blot, qRT-PCR","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — enzyme-substrate interaction with in vitro phosphatase activity and in vivo genetic validation","pmids":["31213464"],"is_preprint":false},{"year":2021,"finding":"In response to oxidative stress, NKX3.1 is imported to mitochondria via the chaperone protein HSPA9, where it regulates transcription of mitochondrial-encoded electron transport chain (ETC) genes, restoring oxidative phosphorylation and preventing cancer initiation; germline polymorphisms of NKX3.1 associated with increased cancer risk fail to protect from oxidative stress.","method":"Mitochondrial fractionation, HSPA9 Co-IP, mitochondrial transcription assay, genetically engineered mouse models, human organotypic cultures, mutant NKX3.1 functional assays","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1–2 — subcellular fractionation with functional validation across multiple models and mutant analysis","pmids":["33893149"],"is_preprint":false},{"year":2021,"finding":"LIMK2 directly phosphorylates NKX3.1, promoting its degradation in castration-resistant prostate cancer cells; NKX3.1 in turn promotes LIMK2 ubiquitylation; this negative crosstalk regulates AR, ARv7, and AKT signaling.","method":"In vitro kinase assay, Co-IP, ubiquitylation assay, siRNA knockdown, in vivo xenograft","journal":"Cancers","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay plus reciprocal functional interaction with in vivo validation","pmids":["34066036"],"is_preprint":false},{"year":2006,"finding":"Nkx3.1 binds Sp-family transcription factors via their respective DNA-binding domains and an N-terminal segment of Nkx3.1, and negatively regulates Sp-mediated transcription of PSA via TSA-sensitive (histone deacetylase-dependent) and TSA-insensitive mechanisms without requiring Nkx3.1's own DNA-binding activity.","method":"Co-immunoprecipitation, reporter assay, HDAC inhibitor (TSA) treatment, domain mutagenesis","journal":"Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus functional reporter assays with domain mapping and pharmacological validation","pmids":["16201967"],"is_preprint":false},{"year":2008,"finding":"Nkx3-1 and LEF-1 bind to ER (estrogen receptor) cis-regulatory elements in vivo, function as transcriptional repressors of estrogen signaling, and can inhibit ER binding to chromatin, demonstrating competition for common chromatin-binding regions.","method":"ChIP, reporter assay, ER chromatin binding assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — ChIP in vivo with functional reporter and ER binding competition assay","pmids":["18794125"],"is_preprint":false},{"year":2010,"finding":"Androgen receptor binds canonical AREs in the NKX3.1 3'UTR (at positions +2378–2392 and +3098–3112) to mediate androgen-dependent upregulation of NKX3.1; AR recruitment confirmed by ChIP and mutational analysis.","method":"Reporter deletion analysis, EMSA, ChIP, site-directed mutagenesis","journal":"Biochemical journal","confidence":"High","confidence_rationale":"Tier 1–2 — EMSA plus ChIP with site-directed mutagenesis confirming ARE function","pmids":["19886863"],"is_preprint":false},{"year":2009,"finding":"NKX3.1 directly activates VEGF-C-repressing transcriptional activity with HDAC1 as corepressor; loss of NKX3.1 leads to increased VEGF-C expression; RalA acts in synergy with NKX3.1 loss to increase VEGF-C transcription.","method":"Reporter assay, Co-IP (NKX3.1-HDAC1), siRNA knockdown, ChIP","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and reporter assay with siRNA knockdown, single lab","pmids":["18974119"],"is_preprint":false},{"year":2013,"finding":"Canonical Wnt signaling regulates Nkx3.1 expression during prostate organogenesis; Nkx3.1 in turn maintains canonical Wnt signaling activity in developing prostate bud tips (positive feedback loop), as shown in urogenital sinus explant cultures and TCF/Lef reporter mice.","method":"Wnt inhibitor treatment of urogenital sinus explants, TCF/Lef:H2B-GFP transgenic reporter mice, Nkx3.1 null neonatal prostates","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic reporter mice plus pharmacological inhibition, single lab","pmids":["23813564"],"is_preprint":false}],"current_model":"NKX3.1 is an androgen-regulated prostate-specific homeodomain transcription factor and haploinsufficient tumor suppressor that binds a TAAGTA consensus sequence to repress or activate target genes (including IGFBP-3, TWIST1, RAMP1, VEGF-C); it maintains prostate differentiation by interacting with G9a histone methyltransferase to activate UTY/KDM6c; suppresses prostate cancer initiation by protecting mitochondrial function (via HSPA9-mediated mitochondrial import and regulation of ETC gene transcription) and enhancing DNA damage repair (by activating ATM kinase, facilitating ATM and γH2AX recruitment, activating topoisomerase I, and promoting homology-directed repair to suppress TMPRSS2-ERG rearrangements); its protein stability is tightly controlled by a network of post-translational modifications including stabilizing phosphorylation by CK2 (Thr89/Thr93) and Pim-1, destabilizing phosphorylation by DYRK1B (Ser185) and LIMK2, inflammatory cytokine-induced phosphorylation at Ser196 leading to ubiquitination by TOPORS and proteasomal degradation, and protection from degradation by nuclear PTEN (which dephosphorylates Ser185); NKX3.1 also cooperates with the AR-FoxA1 transcriptional network, opposes Myc transcriptional activity on shared target genes, and, in non-prostate contexts (T-ALL), is activated by the TAL1-LMO-Ldb1 complex to drive leukemic proliferation and, during iPSC reprogramming, functions downstream of IL-6-STAT3 to activate OCT4."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing NKX3-1 as a prostate-specific, androgen-regulated homeoprotein answered what tissue and hormonal context governs its expression, framing all subsequent functional studies.","evidence":"RNase protection, in situ hybridization, castration, and androgen-stimulation experiments in mouse prostate and LNCaP cells","pmids":["9142502","9537602"],"confidence":"High","gaps":["Cis-regulatory elements mediating androgen regulation not mapped","Protein-level regulation not addressed"]},{"year":1999,"claim":"Targeted disruption showing prostatic hyperplasia and dysplasia even in heterozygotes established NKX3-1 as a haploinsufficient tumor suppressor, resolving its loss-of-function phenotype.","evidence":"Nkx3.1 knockout mice with histopathology and tissue recombinants","pmids":["10215624","11002344"],"confidence":"High","gaps":["Molecular targets mediating growth suppression unknown","Whether loss alone drives cancer or requires cooperating events"]},{"year":2000,"claim":"Identification of the TAAGTA consensus binding site and demonstration of transcriptional repression defined NKX3-1's DNA-binding specificity and mode of transcriptional action.","evidence":"Binding site selection, EMSA, and luciferase reporter assays","pmids":["10871372"],"confidence":"High","gaps":["Genome-wide binding sites not mapped","Cofactors mediating repression unidentified"]},{"year":2002,"claim":"Genetic cooperativity between Nkx3.1 and Pten loss, mediated by synergistic Akt activation, placed NKX3-1 within the PI3K-AKT tumor suppression pathway.","evidence":"Compound mutant mice with phospho-Akt Western blot and histopathology","pmids":["11854455"],"confidence":"High","gaps":["Whether NKX3-1 directly modulates PTEN expression or signaling not resolved","Downstream Akt effectors responsible for cooperativity unidentified"]},{"year":2005,"claim":"Demonstration that Nkx3.1 loss deregulates oxidative stress enzymes and increases 8-OHdG revealed a protective role against oxidative DNA damage, a key early cancer-promoting event.","evidence":"Gene expression profiling and 8-OHdG immunohistochemistry in Nkx3.1 null and compound mutant mice","pmids":["16061659"],"confidence":"High","gaps":["Direct versus indirect transcriptional control of antioxidant genes not distinguished","Functional rescue by restoring individual target genes not tested"]},{"year":2006,"claim":"Multiple studies in 2006 defined NKX3-1's cofactor interactions and post-translational regulation: CK2α′ phosphorylation at Thr89/Thr93 stabilizes the protein; NKX3-1 associates with HDAC1 to increase p53 acetylation; and structural analysis of a hereditary mutation (T164A) demonstrated homeodomain destabilization.","evidence":"In vitro kinase assays with MS, Co-IP for HDAC1, NMR spectroscopy of T164A mutant homeodomain, functional rescue in Pten-null mice","pmids":["16581776","16697957","16397218","16201967","16814806"],"confidence":"High","gaps":["Identity of the kinase responsible for destabilizing Ser185 phosphorylation not yet known","How HDAC1 sequestration by NKX3-1 mechanistically increases p53 acetylation not fully resolved"]},{"year":2007,"claim":"Discovery that NKX3-1 directly binds and activates topoisomerase I, and recruits p300/PCAF for histone acetylation at dosage-sensitive loci, provided the first enzymatic and chromatin-remodeling partners explaining its DNA-damage and transcriptional functions.","evidence":"Affinity pulldown, co-IP, in vitro Topo I activity assays, ChIP for histone acetylation, HDAC inhibitor rescue","pmids":["17234752","17602165","18077445"],"confidence":"High","gaps":["Whether Topo I activation and chromatin remodeling are functionally linked","Structural basis of NKX3-1–Topo I interaction unknown"]},{"year":2008,"claim":"Mapping the inflammation-triggered degradation pathway—TNF-α-induced Ser196 phosphorylation leading to TOPORS-mediated ubiquitination—explained how inflammation accelerates NKX3-1 loss in prostate cancer.","evidence":"Site-directed mutagenesis (S196A, S185A), cytokine treatment, ubiquitination and half-life assays","pmids":["18757402"],"confidence":"High","gaps":["Kinase responsible for Ser196 phosphorylation not identified","In vivo inflammation model not used"]},{"year":2009,"claim":"Identification of IGFBP-3 as a transcriptional target that mediates NKX3-1's attenuation of IGF-I/PI3K/AKT signaling connected NKX3-1 tumor suppression to a defined growth factor signaling axis.","evidence":"Microarray, stable transfection, siRNA knockdown of IGFBP-3, Western blot for IGF pathway phosphorylation","pmids":["19258508"],"confidence":"High","gaps":["Direct binding of NKX3-1 to IGFBP-3 regulatory elements not shown by ChIP at the time","Contribution of IGFBP-3 versus other targets to in vivo tumor suppression not separated"]},{"year":2010,"claim":"NKX3-1 was shown to localize to DNA damage sites and activate ATM kinase autophosphorylation, establishing a direct mechanistic role in the DNA damage response beyond Topo I activation; concurrently, genome-wide ChIP-seq revealed extensive co-occupancy with AR and FoxA1.","evidence":"Immunofluorescence co-localization, ATM kinase assays, siRNA/overexpression, ChIP-seq in LNCaP cells","pmids":["20395202","22083957"],"confidence":"High","gaps":["ATM–NKX3-1 physical interaction not yet mapped to specific domains","How co-occupancy with AR/FoxA1 is mechanistically organized at enhancers"]},{"year":2010,"claim":"In T-ALL, NKX3-1 was identified as a direct target of the TAL1-LMO-Ldb1 oncogenic complex, revealing a non-prostate proliferative function where NKX3-1 promotes leukemic growth via miR-17-92.","evidence":"ChIP at NKX3-1 promoter, siRNA/shRNA knockdown, in vivo leukemia engraftment","pmids":["20855495"],"confidence":"High","gaps":["Targets of NKX3-1 besides miR-17-92 in T-ALL not characterized","Whether NKX3-1 functions as tumor suppressor or oncogene is context-dependent and not reconciled"]},{"year":2013,"claim":"A cluster of studies refined the DNA-damage mechanism: NKX3-1 Tyr222 phosphorylation upon damage enables direct ATM binding and DNA-damage-independent ATM activation; NKX3-1 also modulates Topo I by inhibiting its resolvase activity while enhancing full-length enzyme activity; and NKX3-1 binds the ERG breakpoint to suppress TMPRSS2-ERG rearrangements by favoring homology-directed repair.","evidence":"Co-IP with phospho-mutants, in vitro ATM kinase assay, reconstituted Topo I domain assays, ChIP at ERG breakpoint, FISH for loci juxtaposition","pmids":["23890999","23557481","25977336"],"confidence":"High","gaps":["Kinase responsible for Tyr222 phosphorylation not identified","Structural basis of NKX3-1–ATM interaction unknown"]},{"year":2013,"claim":"Pim-1 kinase was identified as a stabilizer of NKX3-1, phosphorylating multiple residues including Ser185, counteracting the destabilizing pathway and adding complexity to NKX3-1 turnover regulation.","evidence":"Mass spectrometry of phosphosites, Pim-1 inhibitor treatment, mutational analysis, protein half-life assays","pmids":["23129228"],"confidence":"High","gaps":["How Pim-1-mediated phosphorylation at the same site (Ser185) stabilizes while other kinases destabilize is not mechanistically reconciled"]},{"year":2015,"claim":"DYRK1B was identified as the kinase that phosphorylates NKX3-1 Ser185 to trigger steady-state degradation, resolving a long-standing question about the kinase mediating the constitutive turnover pathway.","evidence":"siRNA library screen, in vitro kinase assay, co-IP, protein half-life assay, DYRK1B inhibitors","pmids":["25777618"],"confidence":"High","gaps":["Whether DYRK1B inhibitors can stabilize NKX3-1 in vivo to suppress cancer not tested","Interplay between DYRK1B, Pim-1, and CK2 at overlapping sites not resolved"]},{"year":2016,"claim":"NKX3-1 gain-of-function was shown to respecify seminal vesicle epithelium toward a prostate fate via interaction with the G9a histone methyltransferase and activation of UTY/KDM6c, establishing the chromatin mechanism underlying NKX3-1's role as a master regulator of prostate identity.","evidence":"In vivo renal graft respecification, Co-IP of NKX3-1–G9a, gene expression profiling, loss-of-function mice","pmids":["27339988"],"confidence":"High","gaps":["Genome-wide targets of the NKX3-1–G9a complex not mapped","Whether G9a interaction is required for tumor suppression not tested"]},{"year":2018,"claim":"NKX3-1 was shown to activate endogenous OCT4 downstream of IL-6–STAT3 signaling and substitute for OCT4 in iPSC reprogramming, revealing a previously unsuspected role in pluripotency circuits.","evidence":"Heterokaryon reprogramming, siRNA knockdown, STAT3 inhibition, iPSC generation from mouse and human fibroblasts","pmids":["30013107"],"confidence":"High","gaps":["Mechanism by which NKX3-1 activates OCT4 transcription not defined","Whether this function relates to prostate stem cell biology not addressed"]},{"year":2019,"claim":"Nuclear PTEN was identified as a phosphatase that directly dephosphorylates NKX3-1 Ser185, opposing DYRK1B and stabilizing NKX3-1 protein; this explained why PTEN loss leads to rapid NKX3-1 protein decline and connected two major prostate tumor suppressors in a single post-translational circuit.","evidence":"Co-IP (PTEN–NKX3-1), nuclear localization mutants, protein half-life assay, gene-targeted mice","pmids":["31213464"],"confidence":"High","gaps":["PTEN's phosphatase activity on NKX3-1 not reconstituted with purified components","Whether lipid phosphatase and NKX3-1 phosphatase activities are coordinated"]},{"year":2021,"claim":"NKX3-1 was shown to be imported into mitochondria via HSPA9 to regulate mitochondrial-encoded ETC gene transcription and restore oxidative phosphorylation, providing a mechanistic basis for its protection against oxidative stress and cancer initiation.","evidence":"Mitochondrial fractionation, HSPA9 Co-IP, mitochondrial transcription assay, genetically engineered mice, human organotypic cultures","pmids":["33893149"],"confidence":"High","gaps":["How a homeodomain protein binds mitochondrial DNA promoters is not structurally defined","Relative contribution of mitochondrial versus nuclear functions to tumor suppression not separated"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the NKX3-1–ATM and NKX3-1–mitochondrial DNA interactions, the kinase responsible for damage-induced Tyr222 phosphorylation, how the same Ser185 site mediates opposing stability outcomes depending on kinase context, whether pharmacological stabilization of NKX3-1 (via DYRK1B inhibitors) prevents cancer in vivo, and how NKX3-1's prostate-specific tumor-suppressive versus T-ALL-promoting activities are determined by cellular context.","evidence":"","pmids":[],"confidence":"High","gaps":["Structural basis of NKX3-1–ATM interaction","Kinase for Tyr222 phosphorylation unidentified","In vivo therapeutic efficacy of NKX3-1 stabilization not tested","Context-dependent oncogene vs tumor suppressor function not mechanistically resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,3,12,27,28,31]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,15,19,27,28,32,40]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,14,34]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[35]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,15,21,27,32]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[20,25,26,31]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[15,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,5,6,7,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,4,32,41]}],"complexes":[],"partners":["AR","ATM","TOP1","G9A","HDAC1","TOPORS","PTEN","DYRK1B"],"other_free_text":[]},"mechanistic_narrative":"NKX3-1 is an androgen-regulated, prostate-specific homeodomain transcription factor that functions as a haploinsufficient tumor suppressor by maintaining epithelial differentiation, protecting against oxidative and genotoxic stress, and restraining oncogenic signaling. It binds a TAAGTA consensus sequence to repress targets such as TWIST1, RAMP1, and VEGF-C, and activates others including IGFBP-3, recruiting chromatin-modifying cofactors (HDAC1, p300/PCAF, G9a) to regulate histone acetylation and methylation at target loci [PMID:10871372, PMID:17602165, PMID:27339988, PMID:19258508]. NKX3-1 enhances DNA damage repair by activating ATM kinase and topoisomerase I, promoting homology-directed repair that suppresses TMPRSS2-ERG rearrangements, and protects mitochondrial function through HSPA9-mediated mitochondrial import and regulation of electron transport chain gene transcription [PMID:23890999, PMID:17234752, PMID:25977336, PMID:33893149]. Its protein stability is tightly controlled by stabilizing phosphorylation (CK2 at Thr89/Thr93; Pim-1) and destabilizing phosphorylation (DYRK1B at Ser185; LIMK2), with inflammatory cytokine-induced Ser196 phosphorylation triggering TOPORS-mediated ubiquitination, while nuclear PTEN opposes degradation by dephosphorylating Ser185 [PMID:16581776, PMID:25777618, PMID:18757402, PMID:31213464]."},"prefetch_data":{"uniprot":{"accession":"Q99801","full_name":"Homeobox protein Nkx-3.1","aliases":["Homeobox protein NK-3 homolog A"],"length_aa":234,"mass_kda":26.4,"function":"Transcription factor, which binds preferentially the consensus sequence 5'-TAAGT[AG]-3' and can behave as a transcriptional repressor. Plays an important role in normal prostate development, regulating proliferation of glandular epithelium and in the formation of ducts in prostate. Acts as a tumor suppressor controlling prostate carcinogenesis, as shown by the ability to inhibit proliferation and invasion activities of PC-3 prostate cancer cells","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q99801/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NKX3-1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NKX3-1","total_profiled":1310},"omim":[{"mim_id":"618192","title":"PROSTATE CANCER-ASSOCIATED TRANSCRIPT 19, NONCODING; PCAT19","url":"https://www.omim.org/entry/618192"},{"mim_id":"616387","title":"DOWNREGULATED RNA IN ANDROGEN-INDEPENDENT CELLS, NONCODING; DRAIC","url":"https://www.omim.org/entry/616387"},{"mim_id":"611959","title":"PROSTATE CANCER, HEREDITARY, 15; HPC15","url":"https://www.omim.org/entry/611959"},{"mim_id":"604599","title":"EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE 2; EHMT2","url":"https://www.omim.org/entry/604599"},{"mim_id":"602183","title":"NK3 HOMEOBOX 2; NKX3-2","url":"https://www.omim.org/entry/602183"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"prostate","ntpm":284.6}],"url":"https://www.proteinatlas.org/search/NKX3-1"},"hgnc":{"alias_symbol":["NKX3.1","BAPX2"],"prev_symbol":["NKX3A"]},"alphafold":{"accession":"Q99801","domains":[{"cath_id":"1.10.10.60","chopping":"132-194","consensus_level":"medium","plddt":92.9022,"start":132,"end":194}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99801","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99801-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99801-F1-predicted_aligned_error_v6.png","plddt_mean":65.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NKX3-1","jax_strain_url":"https://www.jax.org/strain/search?query=NKX3-1"},"sequence":{"accession":"Q99801","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99801.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99801/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99801"}},"corpus_meta":[{"pmid":"10215624","id":"PMC_10215624","title":"Roles for Nkx3.1 in prostate development and cancer.","date":"1999","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/10215624","citation_count":511,"is_preprint":false},{"pmid":"11085535","id":"PMC_11085535","title":"Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11085535","citation_count":294,"is_preprint":false},{"pmid":"9226374","id":"PMC_9226374","title":"A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9226374","citation_count":289,"is_preprint":false},{"pmid":"11854455","id":"PMC_11854455","title":"Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11854455","citation_count":258,"is_preprint":false},{"pmid":"20588175","id":"PMC_20588175","title":"NKX3.1 as a marker of prostatic origin in metastatic tumors.","date":"2010","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20588175","citation_count":221,"is_preprint":false},{"pmid":"12036903","id":"PMC_12036903","title":"Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12036903","citation_count":201,"is_preprint":false},{"pmid":"11839815","id":"PMC_11839815","title":"Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11839815","citation_count":190,"is_preprint":false},{"pmid":"22083957","id":"PMC_22083957","title":"Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22083957","citation_count":148,"is_preprint":false},{"pmid":"9142502","id":"PMC_9142502","title":"Tissue-specific expression of murine Nkx3.1 in the male urogenital system.","date":"1997","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/9142502","citation_count":145,"is_preprint":false},{"pmid":"16697957","id":"PMC_16697957","title":"NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.","date":"2006","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/16697957","citation_count":143,"is_preprint":false},{"pmid":"15734999","id":"PMC_15734999","title":"Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15734999","citation_count":132,"is_preprint":false},{"pmid":"16061659","id":"PMC_16061659","title":"Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16061659","citation_count":124,"is_preprint":false},{"pmid":"9377551","id":"PMC_9377551","title":"Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9377551","citation_count":119,"is_preprint":false},{"pmid":"20479932","id":"PMC_20479932","title":"ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20479932","citation_count":118,"is_preprint":false},{"pmid":"12676585","id":"PMC_12676585","title":"Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation.","date":"2003","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12676585","citation_count":111,"is_preprint":false},{"pmid":"9537602","id":"PMC_9537602","title":"Isolation and androgen regulation of the human homeobox cDNA, NKX3.1.","date":"1998","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/9537602","citation_count":107,"is_preprint":false},{"pmid":"20195545","id":"PMC_20195545","title":"MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20195545","citation_count":103,"is_preprint":false},{"pmid":"18557759","id":"PMC_18557759","title":"Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.","date":"2008","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/18557759","citation_count":99,"is_preprint":false},{"pmid":"10906459","id":"PMC_10906459","title":"Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10906459","citation_count":89,"is_preprint":false},{"pmid":"14648854","id":"PMC_14648854","title":"Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.","date":"2003","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/14648854","citation_count":85,"is_preprint":false},{"pmid":"19597465","id":"PMC_19597465","title":"Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19597465","citation_count":81,"is_preprint":false},{"pmid":"11002344","id":"PMC_11002344","title":"Nkx3.1, a murine homolog of Ddrosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands.","date":"2000","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/11002344","citation_count":81,"is_preprint":false},{"pmid":"27339988","id":"PMC_27339988","title":"Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation.","date":"2016","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/27339988","citation_count":76,"is_preprint":false},{"pmid":"12661036","id":"PMC_12661036","title":"Expression of NKX3.1 in normal and malignant tissues.","date":"2003","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/12661036","citation_count":74,"is_preprint":false},{"pmid":"20363913","id":"PMC_20363913","title":"Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia.","date":"2010","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20363913","citation_count":68,"is_preprint":false},{"pmid":"17020998","id":"PMC_17020998","title":"Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17020998","citation_count":66,"is_preprint":false},{"pmid":"17909013","id":"PMC_17909013","title":"Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17909013","citation_count":65,"is_preprint":false},{"pmid":"31972596","id":"PMC_31972596","title":"NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31972596","citation_count":61,"is_preprint":false},{"pmid":"11257711","id":"PMC_11257711","title":"Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium.","date":"2001","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/11257711","citation_count":60,"is_preprint":false},{"pmid":"20395202","id":"PMC_20395202","title":"NKX3.1 activates cellular response to DNA damage.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20395202","citation_count":57,"is_preprint":false},{"pmid":"20855495","id":"PMC_20855495","title":"NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.","date":"2010","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20855495","citation_count":57,"is_preprint":false},{"pmid":"18757402","id":"PMC_18757402","title":"Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18757402","citation_count":53,"is_preprint":false},{"pmid":"22484818","id":"PMC_22484818","title":"Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22484818","citation_count":52,"is_preprint":false},{"pmid":"10871372","id":"PMC_10871372","title":"DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1.","date":"2000","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10871372","citation_count":52,"is_preprint":false},{"pmid":"10415359","id":"PMC_10415359","title":"Expression of the Nkx3.1 homobox gene during pre and postnatal development.","date":"1999","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10415359","citation_count":43,"is_preprint":false},{"pmid":"30013107","id":"PMC_30013107","title":"NKX3-1 is required for induced pluripotent stem cell reprogramming and can replace OCT4 in mouse and human iPSC induction.","date":"2018","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30013107","citation_count":43,"is_preprint":false},{"pmid":"17234752","id":"PMC_17234752","title":"NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17234752","citation_count":42,"is_preprint":false},{"pmid":"11137288","id":"PMC_11137288","title":"Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11137288","citation_count":41,"is_preprint":false},{"pmid":"12204261","id":"PMC_12204261","title":"Transcription factors Nkx3.1 and Nkx3.2 (Bapx1) play an overlapping role in sclerotomal development of the mouse.","date":"2002","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/12204261","citation_count":41,"is_preprint":false},{"pmid":"18077445","id":"PMC_18077445","title":"Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18077445","citation_count":39,"is_preprint":false},{"pmid":"16382041","id":"PMC_16382041","title":"Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1.","date":"2005","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16382041","citation_count":37,"is_preprint":false},{"pmid":"18794125","id":"PMC_18794125","title":"Nkx3-1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18794125","citation_count":36,"is_preprint":false},{"pmid":"16581776","id":"PMC_16581776","title":"NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16581776","citation_count":36,"is_preprint":false},{"pmid":"23813564","id":"PMC_23813564","title":"Canonical Wnt signaling regulates Nkx3.1 expression and luminal epithelial differentiation during prostate organogenesis.","date":"2013","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/23813564","citation_count":36,"is_preprint":false},{"pmid":"19797053","id":"PMC_19797053","title":"Myocardin-dependent activation of the CArG box-rich smooth muscle gamma-actin gene: preferential utilization of a single CArG element through functional association with the NKX3.1 homeodomain protein.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19797053","citation_count":36,"is_preprint":false},{"pmid":"33893149","id":"PMC_33893149","title":"NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation.","date":"2021","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33893149","citation_count":35,"is_preprint":false},{"pmid":"17303007","id":"PMC_17303007","title":"Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP.","date":"2007","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/17303007","citation_count":35,"is_preprint":false},{"pmid":"25977336","id":"PMC_25977336","title":"NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25977336","citation_count":35,"is_preprint":false},{"pmid":"16397218","id":"PMC_16397218","title":"Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16397218","citation_count":35,"is_preprint":false},{"pmid":"28555048","id":"PMC_28555048","title":"Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28555048","citation_count":35,"is_preprint":false},{"pmid":"23890999","id":"PMC_23890999","title":"Functional activation of ATM by the prostate cancer suppressor NKX3.1.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23890999","citation_count":34,"is_preprint":false},{"pmid":"30266798","id":"PMC_30266798","title":"Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation.","date":"2018","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30266798","citation_count":33,"is_preprint":false},{"pmid":"24030851","id":"PMC_24030851","title":"Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis.","date":"2013","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/24030851","citation_count":33,"is_preprint":false},{"pmid":"15311057","id":"PMC_15311057","title":"Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis.","date":"2004","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/15311057","citation_count":32,"is_preprint":false},{"pmid":"23836514","id":"PMC_23836514","title":"Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth.","date":"2013","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/23836514","citation_count":32,"is_preprint":false},{"pmid":"23368843","id":"PMC_23368843","title":"TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells.","date":"2013","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/23368843","citation_count":32,"is_preprint":false},{"pmid":"20716579","id":"PMC_20716579","title":"A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20716579","citation_count":32,"is_preprint":false},{"pmid":"11980664","id":"PMC_11980664","title":"Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11980664","citation_count":32,"is_preprint":false},{"pmid":"18974119","id":"PMC_18974119","title":"Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18974119","citation_count":30,"is_preprint":false},{"pmid":"17311278","id":"PMC_17311278","title":"Overexpression HERG K(+) channel gene mediates cell-growth signals on activation of oncoproteins SP1 and NF-kappaB and inactivation of tumor suppressor Nkx3.1.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17311278","citation_count":29,"is_preprint":false},{"pmid":"26313654","id":"PMC_26313654","title":"MiR-378b Promotes Differentiation of Keratinocytes through NKX3.1.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26313654","citation_count":28,"is_preprint":false},{"pmid":"25360740","id":"PMC_25360740","title":"TNFα-mediated loss of β-catenin/E-cadherin association and subsequent increase in cell migration is partially restored by NKX3.1 expression in prostate cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25360740","citation_count":28,"is_preprint":false},{"pmid":"31213464","id":"PMC_31213464","title":"Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31213464","citation_count":27,"is_preprint":false},{"pmid":"17602165","id":"PMC_17602165","title":"Haploinsufficient prostate tumor suppression by Nkx3.1: a role for chromatin accessibility in dosage-sensitive gene regulation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17602165","citation_count":27,"is_preprint":false},{"pmid":"16245334","id":"PMC_16245334","title":"Distinct regulatory elements mediate the dynamic expression pattern of Nkx3.1.","date":"2005","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/16245334","citation_count":26,"is_preprint":false},{"pmid":"16413692","id":"PMC_16413692","title":"Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.","date":"2006","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/16413692","citation_count":26,"is_preprint":false},{"pmid":"16201967","id":"PMC_16201967","title":"Nkx3.1 binds and negatively regulates the transcriptional activity of Sp-family members in prostate-derived cells.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16201967","citation_count":25,"is_preprint":false},{"pmid":"21456068","id":"PMC_21456068","title":"Chromosome 8 markers of metastatic prostate cancer in African American men: gain of the MIR151 gene and loss of the NKX3-1 gene.","date":"2010","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/21456068","citation_count":25,"is_preprint":false},{"pmid":"19886863","id":"PMC_19886863","title":"Androgen regulation of the prostatic tumour suppressor NKX3.1 is mediated by its 3' untranslated region.","date":"2010","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19886863","citation_count":24,"is_preprint":false},{"pmid":"35834096","id":"PMC_35834096","title":"NKX3.1 Expression in Salivary Gland \"Intraductal\" Papillary Mucinous Neoplasm: A Low-Grade Subtype of Salivary Gland Mucinous Adenocarcinoma.","date":"2022","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35834096","citation_count":24,"is_preprint":false},{"pmid":"24996432","id":"PMC_24996432","title":"NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.","date":"2014","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24996432","citation_count":23,"is_preprint":false},{"pmid":"15111307","id":"PMC_15111307","title":"Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15111307","citation_count":23,"is_preprint":false},{"pmid":"23867798","id":"PMC_23867798","title":"RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23867798","citation_count":22,"is_preprint":false},{"pmid":"25777618","id":"PMC_25777618","title":"The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25777618","citation_count":20,"is_preprint":false},{"pmid":"24894197","id":"PMC_24894197","title":"A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).","date":"2014","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/24894197","citation_count":20,"is_preprint":false},{"pmid":"28679531","id":"PMC_28679531","title":"Transcriptional regulation of the Nkx3.1 gene in prostate luminal stem cell specification and cancer initiation via its 3' genomic region.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28679531","citation_count":20,"is_preprint":false},{"pmid":"33632988","id":"PMC_33632988","title":"The Role of Nkx3.1 in Cancers and Stemness.","date":"2021","source":"International journal of stem cells","url":"https://pubmed.ncbi.nlm.nih.gov/33632988","citation_count":19,"is_preprint":false},{"pmid":"23077524","id":"PMC_23077524","title":"Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23077524","citation_count":19,"is_preprint":false},{"pmid":"23786676","id":"PMC_23786676","title":"Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23786676","citation_count":19,"is_preprint":false},{"pmid":"34066036","id":"PMC_34066036","title":"LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34066036","citation_count":18,"is_preprint":false},{"pmid":"26841725","id":"PMC_26841725","title":"Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants.","date":"2016","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/26841725","citation_count":18,"is_preprint":false},{"pmid":"16814806","id":"PMC_16814806","title":"Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16814806","citation_count":18,"is_preprint":false},{"pmid":"23129228","id":"PMC_23129228","title":"Stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells.","date":"2013","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23129228","citation_count":18,"is_preprint":false},{"pmid":"29665565","id":"PMC_29665565","title":"Evaluation of NKX3.1 and C-MYC expression in canine prostatic cancer.","date":"2018","source":"Research in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/29665565","citation_count":17,"is_preprint":false},{"pmid":"14633588","id":"PMC_14633588","title":"NKX3.1 expression is lost in testicular germ cell tumors.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14633588","citation_count":17,"is_preprint":false},{"pmid":"19258508","id":"PMC_19258508","title":"NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19258508","citation_count":17,"is_preprint":false},{"pmid":"17929276","id":"PMC_17929276","title":"Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.","date":"2007","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/17929276","citation_count":16,"is_preprint":false},{"pmid":"31175351","id":"PMC_31175351","title":"Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.","date":"2019","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31175351","citation_count":16,"is_preprint":false},{"pmid":"31498176","id":"PMC_31498176","title":"NKX3.1 and Prostein Expression in Testicular Tissue and Sex Cord-stromal Tumors.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31498176","citation_count":16,"is_preprint":false},{"pmid":"24434284","id":"PMC_24434284","title":"DNA damage response (DDR) via NKX3.1 expression in prostate cells.","date":"2014","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24434284","citation_count":16,"is_preprint":false},{"pmid":"33302222","id":"PMC_33302222","title":"NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study.","date":"2020","source":"Annals of diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33302222","citation_count":16,"is_preprint":false},{"pmid":"23557481","id":"PMC_23557481","title":"Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23557481","citation_count":16,"is_preprint":false},{"pmid":"28972178","id":"PMC_28972178","title":"NK3 homeobox 1 (NKX3.1) up-regulates forkhead box O1 expression in hepatocellular carcinoma and thereby suppresses tumor proliferation and invasion.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28972178","citation_count":16,"is_preprint":false},{"pmid":"25705129","id":"PMC_25705129","title":"Inflammation contributes to NKX3.1 loss and augments DNA damage but does not alter the DNA damage response via increased SIRT1 expression.","date":"2015","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25705129","citation_count":16,"is_preprint":false},{"pmid":"17078065","id":"PMC_17078065","title":"Expression of an Nkx3.1-CRE gene using ROSA26 reporter mice.","date":"2006","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/17078065","citation_count":15,"is_preprint":false},{"pmid":"28385453","id":"PMC_28385453","title":"Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.","date":"2017","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/28385453","citation_count":15,"is_preprint":false},{"pmid":"32202926","id":"PMC_32202926","title":"Roles of CCNB2 and NKX3-1 in Nasopharyngeal Carcinoma.","date":"2020","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/32202926","citation_count":14,"is_preprint":false},{"pmid":"33021555","id":"PMC_33021555","title":"Skene's Gland Derivatives in the Female Genital Tract and Cervical Adenoid Basal Carcinoma are Consistently Positive With Prostatic Marker NKX3.1.","date":"2021","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/33021555","citation_count":14,"is_preprint":false},{"pmid":"26208047","id":"PMC_26208047","title":"An EG-VEGF-Dependent Decrease in Homeobox Gene NKX3.1 Contributes to Cytotrophoblast Dysfunction: A Possible Mechanism in Human Fetal Growth Restriction.","date":"2015","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/26208047","citation_count":14,"is_preprint":false},{"pmid":"19266349","id":"PMC_19266349","title":"Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.","date":"2009","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19266349","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51146,"output_tokens":9358,"usd":0.146904},"stage2":{"model":"claude-opus-4-6","input_tokens":13318,"output_tokens":4625,"usd":0.273323},"total_usd":0.420227,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"NKX3.1 encodes a 38 kDa homeoprotein with DNA binding properties similar to other Nkx family members; it is expressed in a prostate-specific and androgen-regulated manner, with castration significantly reducing expression, establishing androgen dependence for maintenance.\",\n      \"method\": \"RNase protection analysis, in situ hybridization, castration experiments\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, foundational characterization paper, highly cited\",\n      \"pmids\": [\"9142502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NKX3.1 mRNA is induced 6–7 fold by androgens in LNCaP cells within 12 hours, at the level of transcription and independent of de novo protein synthesis, establishing androgen receptor-mediated transcriptional regulation.\",\n      \"method\": \"Differential display PCR, Northern blot, androgen stimulation, transcription inhibition assays\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, replicated across studies\",\n      \"pmids\": [\"9537602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Nkx3.1 null mutation (targeted gene disruption) results in defects in prostate ductal morphogenesis, secretory protein production, and progressive prostatic epithelial hyperplasia and dysplasia; haploinsufficiency is sufficient to cause these phenotypes, establishing Nkx3.1 as a prostate tumor suppressor with growth-suppressive roles in prostatic epithelium.\",\n      \"method\": \"Targeted gene disruption, histopathology, tissue recombinants\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotypic readout, replicated by multiple labs, >500 citations\",\n      \"pmids\": [\"10215624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"NKX3.1 binds a novel TAAGTA consensus DNA sequence (distinct from other NK family members) with ~20 nM affinity, and functions as a transcriptional repressor from this site in reporter assays.\",\n      \"method\": \"Binding site selection assay, EMSA, luciferase reporter assay, competitive gel shift with mutated binding sites\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution with mutagenesis and functional validation\",\n      \"pmids\": [\"10871372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Targeted disruption of Nkx3.1 causes defective branching morphogenesis and epithelial hyperplasia in prostate and palatine glands, with no effects on sclerotome, blood vessels, kidney, or brain, demonstrating organ-specific roles.\",\n      \"method\": \"Targeted gene disruption, histological analysis\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with specific phenotypic readout, replicated findings\",\n      \"pmids\": [\"11002344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Loss of Nkx3.1 cooperates with loss of Pten in prostate cancer progression, with cooperativity mediated by synergistic activation of Akt (PKB), establishing Nkx3.1 within the PTEN-AKT signaling pathway.\",\n      \"method\": \"Compound mutant mouse models, Western blot for phospho-Akt, histopathology\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with molecular readout, highly cited\",\n      \"pmids\": [\"11854455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Conditional Cre/loxP-mediated deletion of Nkx3.1 in adult mouse prostate (one or both alleles) leads to PIN-like lesions; PIN foci in single-allele conditional knockouts lose expression of the wild-type allele, supporting haploinsufficiency and tumor suppressor role.\",\n      \"method\": \"Conditional Cre/loxP recombination, immunohistochemistry for Ki-67/E-cadherin/cytokeratins\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined cellular phenotype, mechanistically informative\",\n      \"pmids\": [\"11839815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Nkx3.1 displays growth-suppressing activities in cell culture and aged Nkx3.1 mutant mice develop PIN-like histopathological lesions that undergo progressively severe alterations after serial transplantation in nude mice.\",\n      \"method\": \"Cell culture growth assays, histopathology, tissue recombination/serial transplantation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular and in vivo phenotype\",\n      \"pmids\": [\"12036903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Nkx3.1 haploinsufficiency extends the proliferative stage of regenerating luminal cells; the number of Nkx3.1 alleles determines the probability of stochastic activation or inactivation of dosage-sensitive target genes, as revealed by microarray analysis.\",\n      \"method\": \"Mouse model analysis, microarray gene expression profiling, histopathology\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in vivo and in vitro establishing mechanistic principle\",\n      \"pmids\": [\"12676585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Loss-of-function of Nkx3.1 leads to deregulated expression of antioxidant and prooxidant enzymes (GPx2, GPx3, Prdx6, Qscn6) and increased oxidative DNA damage (8-OHdG), linking Nkx3.1 to protection of prostatic epithelium against oxidative stress.\",\n      \"method\": \"Gene expression profiling, immunohistochemistry for 8-OHdG, Nkx3.1 null and compound mutant mice\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function mouse model with molecular mechanistic readout\",\n      \"pmids\": [\"16061659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NKX3.1 associates with HDAC1, leading to increased p53 acetylation and p53 half-life via MDM2-dependent mechanisms; NKX3.1 also negatively modulates AR transcription and blocks AKT activation in PTEN-null prostate epithelium.\",\n      \"method\": \"Co-immunoprecipitation, in vivo restoration of Nkx3.1 in Pten-null mice, proliferation/apoptosis assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus in vivo rescue experiment, multiple mechanistic endpoints\",\n      \"pmids\": [\"16697957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NKX3.1 is regulated by protein kinase CK2: CK2 phosphorylates NKX3.1 on Thr89 and Thr93 in vitro, and CK2 activity is required for NKX3.1 stability in cells; specifically, free CK2α' (not holoenzyme) phosphorylates NKX3.1, establishing CK2α' as a regulator of NKX3.1 stability.\",\n      \"method\": \"In vitro kinase assay with mass spectrometry, CK2 inhibitors, siRNA knockdown, in-gel kinase assay, mutational analysis (T89A/T93A)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with MS identification of phosphosites plus mutagenesis and cellular validation\",\n      \"pmids\": [\"16581776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A germline T164A mutation in the NKX3.1 homeodomain (found in a hereditary prostate cancer family) alters homeodomain stability and decreases DNA-binding activity, as determined by NMR solution structure and circular dichroism.\",\n      \"method\": \"NMR spectroscopy, circular dichroism, DNA binding assays, family genetic analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural (NMR) plus functional validation\",\n      \"pmids\": [\"16397218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NKX3.1 physically interacts with serum response factor (SRF) via three N-terminal motifs (TN/EH-1 motif residues 29–35, SI motif residues 99–105, and acidic domain residues 88–96) and acts as a transcriptional co-activator of the smooth muscle gamma-actin promoter.\",\n      \"method\": \"NMR spectroscopy, targeted mutagenesis, SMGA reporter assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure determination plus mutagenesis with functional reporter validation\",\n      \"pmids\": [\"16814806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NKX3.1 directly binds topoisomerase I (Topo I) via its homeodomain (with Topo I core-linker domain junction), enhances Topo I-DNA complex formation and Topo I DNA cleavage activity; endogenous NKX3.1 and Topo I co-immunoprecipitate and co-localize in the nucleus, co-migrating to DNA damage sites after genotoxic stress. Topo I activity in prostates of Nkx3.1 null mice is reduced compared to wild-type.\",\n      \"method\": \"Affinity column pulldown, co-IP from LNCaP cells, in vitro Topo I activity assays, co-localization by immunofluorescence, genetically engineered mice\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical reconstitution plus in vivo genetic validation and cellular co-localization\",\n      \"pmids\": [\"17234752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The NKX3.1 haploinsufficiency phenotype is linked to differential histone H3/H4 acetylation states of dosage-sensitive target genes; NKX3.1 associates with and recruits the histone acetyltransferase p300/PCAF (p300/CBP-associated factor) to chromatin to regulate target gene expression.\",\n      \"method\": \"ChIP for histone acetylation, HDAC inhibitor (TSA) rescue, co-immunoprecipitation for p300/PCAF\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus ChIP with pharmacological rescue, mechanistically coherent\",\n      \"pmids\": [\"17602165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TOPORS, an E3 ubiquitin ligase, interacts with NKX3.1, ubiquitinates it in vitro and in vivo, and overexpression of TOPORS leads to NKX3.1 proteasomal degradation; siRNA knockdown of TOPORS increases NKX3.1 steady-state level and half-life.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, siRNA knockdown, protein half-life assay\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro ubiquitination assay plus cellular gain/loss-of-function experiments\",\n      \"pmids\": [\"18077445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Inflammatory cytokines TNF-α and IL-1β accelerate NKX3.1 protein loss by inducing rapid ubiquitination and proteasomal degradation; TNF-α acts via phosphorylation of C-terminal serine 196 (mutation S196A abrogates this); steady-state NKX3.1 turnover is controlled by serine 185; serine 195 has a modulating role on both pathways.\",\n      \"method\": \"Site-directed mutagenesis (S196A, S185A, S195A), cytokine treatment, ubiquitination assays, protein half-life measurements\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis mapping of phosphosites with functional ubiquitination and degradation assays\",\n      \"pmids\": [\"18757402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NKX3.1 physically interacts with MYOCD (myocardin) and is required for full MYOCD-dependent transactivation of the ACTG2 promoter through an NKX3.1 binding site adjacent to CArG2; functional association demonstrated by co-IP, GST pulldown, and luciferase assays.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, luciferase reporter assay, gel shift assay\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical interaction (Co-IP + GST pulldown) plus functional reporter assay\",\n      \"pmids\": [\"19797053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NKX3.1 activates expression of IGFBP-3 mRNA and protein ~10-fold; this activation attenuates IGF-I-induced phosphorylation of IGF-IR, IRS-1, PI3K, and AKT; siRNA knockdown of IGFBP-3 partially reverses NKX3.1's growth-suppressive effects, establishing IGFBP-3 as a downstream mediator of NKX3.1 tumor suppression.\",\n      \"method\": \"Expression microarray, stable transfection, siRNA knockdown, Western blot for signaling intermediates, proliferation assays, Nkx3.1 gene-targeted mice\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in vitro and in vivo\",\n      \"pmids\": [\"19258508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NKX3.1 localizes to sites of DNA damage, enhances ATM autophosphorylation at Ser1981, activates ATR (via CHK1 phosphorylation), and affects recruitment of phospho-ATM and H2AX phosphorylation at DNA damage foci; an inherited DNA-binding mutant is devoid of ATM activation and γH2AX co-localization.\",\n      \"method\": \"Immunofluorescence co-localization, siRNA knockdown of NKX3.1 in LNCaP, overexpression in PC-3, colony formation after DNA damage, ATM kinase activation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking NKX3.1 to DNA damage response machinery with mutant validation\",\n      \"pmids\": [\"20395202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NKX3.1 co-localizes genome-wide with the androgen receptor (AR) as shown by ChIP-seq; NKX3.1 and AR directly regulate each other in a feed-forward loop; NKX3.1 collaborates with AR and FoxA1 to regulate a gene network including RAB3B, a RAB GTPase that promotes prostate cancer cell survival.\",\n      \"method\": \"ChIP-seq, luciferase reporter assay, siRNA knockdown, gene expression profiling\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq plus functional knockdown with defined transcriptional network\",\n      \"pmids\": [\"22083957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NKX3.1 is a direct transcriptional target of the TAL1-LMO-Ldb1 complex (recruited by GATA-3 to the NKX3.1 promoter) in T-ALL cells; NKX3.1 activation is associated with suppression of HP1-α and chromatin opening at its promoter; NKX3.1 is required for T-ALL proliferation and directly regulates miR-17-92.\",\n      \"method\": \"ChIP, siRNA/shRNA knockdown, reporter assays, in vivo leukemia engraftment\",\n      \"journal\": \"Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct complex recruitment plus functional knockdown with proliferation and in vivo engraftment readouts\",\n      \"pmids\": [\"20855495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ERG and ESE3 ETS factors control Nkx3.1 expression both directly (binding to NKX3.1 gene regulatory elements) and indirectly through regulation of EZH2 (Polycomb Group protein), which epigenetically silences Nkx3.1.\",\n      \"method\": \"ChIP, reporter assay, siRNA knockdown, gene expression profiling\",\n      \"journal\": \"PLoS One\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with functional reporter assays and siRNA knockdown across multiple cell lines\",\n      \"pmids\": [\"20479932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Nkx3.1 and Myc directly bind and crossregulate shared target genes in prostate epithelial cells; Nkx3.1 can oppose Myc transcriptional activity; loss of Nkx3.1 cooperates with Myc overexpression to promote prostate cancer in transgenic mice.\",\n      \"method\": \"ChIP-seq, gene expression profiling, reporter assays, transgenic mice with compound mutations\",\n      \"journal\": \"Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq plus in vivo genetic cooperativity model\",\n      \"pmids\": [\"22484818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NKX3.1 undergoes phosphorylation at tyrosine 222 within minutes of DNA damage, which is required for functional interaction with ATM kinase N-terminal domain; NKX3.1 binding to ATM accelerates ATM activation, hastens γH2AX formation, and enhances ATM kinase activity in a DNA-damage-independent manner; ATM then phosphorylates NKX3.1, leading to its ubiquitination and degradation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ATM kinase assay, phospho-mutant analysis, γH2AX kinetics assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay plus Co-IP with phospho-mutant validation\",\n      \"pmids\": [\"23890999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NKX3.1 homeodomain binds the topoisomerase I core-linker domain junction; NKX3.1 inhibits the DNA-resolving activity of reconstituted Topo I in vitro while enhancing full-length Topo I activity; Topo I knockdown blocks NKX3.1's effect on clonogenicity after DNA damage.\",\n      \"method\": \"In vitro Topo I activity assay with reconstituted enzyme fragments, domain mapping, siRNA knockdown, clonogenic survival assay\",\n      \"journal\": \"Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with domain mapping and cellular validation\",\n      \"pmids\": [\"23557481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NKX3.1 represses TWIST1 expression by directly binding to the TWIST1 promoter; NKX3.1 overexpression reduces TWIST1 promoter reporter activity, and NKX3.1 siRNA upregulates endogenous TWIST1, establishing TWIST1 as a direct NKX3.1 target gene involved in EMT.\",\n      \"method\": \"ChIP, luciferase reporter assay, siRNA knockdown, RT-PCR\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay and gain/loss-of-function with multiple methods\",\n      \"pmids\": [\"23368843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NKX3.1 represses RAMP1 expression by directly binding multiple sites in the RAMP1 locus; loss of NKX3.1 in knockout mice elevates RAMP1, and knockdown of RAMP1 in prostate cancer cells decreases proliferation, tumorigenicity, and MEK-ERK signaling.\",\n      \"method\": \"ChIP-seq, gene expression profiling, shRNA knockdown, xenograft tumor model\",\n      \"journal\": \"American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq with in vivo mouse genetics and functional cellular/xenograft validation\",\n      \"pmids\": [\"23867798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Pim-1 kinase stabilizes NKX3.1 protein by phosphorylating it at Thr89, Ser185, Ser186, Ser195, and Ser196; Pim-1-mediated stabilization requires phosphorylation at Ser185, Ser186, and N-terminal PEST domain and Lys182, protecting NKX3.1 from proteasomal degradation.\",\n      \"method\": \"Mass spectrometry identification of phosphosites, Pim-1 inhibitor treatment, mutational analysis, protein half-life assay, proteasome inhibitor rescue\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS-identified phosphosites with mutagenesis and pharmacological validation\",\n      \"pmids\": [\"23129228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DYRK1B kinase directly phosphorylates NKX3.1 at serine 185 (the residue critical for steady-state turnover) via its kinase domain interaction with NKX3.1; DYRK1B inhibitors prolong NKX3.1 half-life.\",\n      \"method\": \"siRNA library screen, in vitro kinase assay, co-IP (DYRK1B kinase domain), protein half-life assay, small-molecule inhibition\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with substrate identification and pharmacological validation\",\n      \"pmids\": [\"25777618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NKX3.1 binds at the ERG gene breakpoint, inhibits juxtaposition of TMPRSS2 and ERG gene loci, suppresses their recombination, and promotes homology-directed DNA repair; loss of NKX3.1 favors error-prone non-homologous end-joining at the ERG breakpoint.\",\n      \"method\": \"ChIP at ERG breakpoint, FISH for loci juxtaposition, DNA repair pathway factor recruitment assays, human tissue correlation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus mechanistic DNA repair pathway analysis with clinical correlation\",\n      \"pmids\": [\"25977336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NKX3.1 gain-of-function in seminal vesicle epithelium is sufficient to respecify it toward a prostate fate in renal grafts; this activity requires interaction of NKX3.1 with the G9a histone methyltransferase via the homeodomain, and is mediated by activation of UTY (KDM6c), identifying an NKX3.1-G9a-UTY transcriptional regulatory network essential for prostate differentiation.\",\n      \"method\": \"In vivo renal graft respecification, Co-IP (NKX3.1-G9a interaction), gene expression profiling, loss-of-function mouse models\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo gain-of-function respecification plus Co-IP and molecular network characterization\",\n      \"pmids\": [\"27339988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NKX3-1 functions downstream of the IL-6-STAT3 signaling pathway to activate endogenous OCT4 expression during reprogramming; NKX3-1 can substitute for exogenous OCT4 to generate fully pluripotent iPSCs from both mouse and human fibroblasts.\",\n      \"method\": \"Heterokaryon reprogramming system, siRNA knockdown, STAT3 pathway inhibition, iPSC generation and characterization\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (IL-6-STAT3-NKX3-1-OCT4) plus functional iPSC generation with knockdown rescue\",\n      \"pmids\": [\"30013107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PTEN functions as a phosphatase of NKX3.1, opposing DYRK1B-mediated phosphorylation at Ser185 and prolonging NKX3.1 half-life; PTEN and NKX3.1 interact primarily in the nucleus (nuclear PTEN localization is required); loss of PTEN in gene-targeted mice leads to rapid decrease in Nkx3.1 protein without affecting Nkx3.1 mRNA.\",\n      \"method\": \"Co-IP (PTEN-NKX3.1), mutational analysis (nuclear localization signal of PTEN), protein half-life assay, gene-targeted mice, Western blot, qRT-PCR\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — enzyme-substrate interaction with in vitro phosphatase activity and in vivo genetic validation\",\n      \"pmids\": [\"31213464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In response to oxidative stress, NKX3.1 is imported to mitochondria via the chaperone protein HSPA9, where it regulates transcription of mitochondrial-encoded electron transport chain (ETC) genes, restoring oxidative phosphorylation and preventing cancer initiation; germline polymorphisms of NKX3.1 associated with increased cancer risk fail to protect from oxidative stress.\",\n      \"method\": \"Mitochondrial fractionation, HSPA9 Co-IP, mitochondrial transcription assay, genetically engineered mouse models, human organotypic cultures, mutant NKX3.1 functional assays\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — subcellular fractionation with functional validation across multiple models and mutant analysis\",\n      \"pmids\": [\"33893149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LIMK2 directly phosphorylates NKX3.1, promoting its degradation in castration-resistant prostate cancer cells; NKX3.1 in turn promotes LIMK2 ubiquitylation; this negative crosstalk regulates AR, ARv7, and AKT signaling.\",\n      \"method\": \"In vitro kinase assay, Co-IP, ubiquitylation assay, siRNA knockdown, in vivo xenograft\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay plus reciprocal functional interaction with in vivo validation\",\n      \"pmids\": [\"34066036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Nkx3.1 binds Sp-family transcription factors via their respective DNA-binding domains and an N-terminal segment of Nkx3.1, and negatively regulates Sp-mediated transcription of PSA via TSA-sensitive (histone deacetylase-dependent) and TSA-insensitive mechanisms without requiring Nkx3.1's own DNA-binding activity.\",\n      \"method\": \"Co-immunoprecipitation, reporter assay, HDAC inhibitor (TSA) treatment, domain mutagenesis\",\n      \"journal\": \"Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional reporter assays with domain mapping and pharmacological validation\",\n      \"pmids\": [\"16201967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Nkx3-1 and LEF-1 bind to ER (estrogen receptor) cis-regulatory elements in vivo, function as transcriptional repressors of estrogen signaling, and can inhibit ER binding to chromatin, demonstrating competition for common chromatin-binding regions.\",\n      \"method\": \"ChIP, reporter assay, ER chromatin binding assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in vivo with functional reporter and ER binding competition assay\",\n      \"pmids\": [\"18794125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Androgen receptor binds canonical AREs in the NKX3.1 3'UTR (at positions +2378–2392 and +3098–3112) to mediate androgen-dependent upregulation of NKX3.1; AR recruitment confirmed by ChIP and mutational analysis.\",\n      \"method\": \"Reporter deletion analysis, EMSA, ChIP, site-directed mutagenesis\",\n      \"journal\": \"Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — EMSA plus ChIP with site-directed mutagenesis confirming ARE function\",\n      \"pmids\": [\"19886863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NKX3.1 directly activates VEGF-C-repressing transcriptional activity with HDAC1 as corepressor; loss of NKX3.1 leads to increased VEGF-C expression; RalA acts in synergy with NKX3.1 loss to increase VEGF-C transcription.\",\n      \"method\": \"Reporter assay, Co-IP (NKX3.1-HDAC1), siRNA knockdown, ChIP\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and reporter assay with siRNA knockdown, single lab\",\n      \"pmids\": [\"18974119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Canonical Wnt signaling regulates Nkx3.1 expression during prostate organogenesis; Nkx3.1 in turn maintains canonical Wnt signaling activity in developing prostate bud tips (positive feedback loop), as shown in urogenital sinus explant cultures and TCF/Lef reporter mice.\",\n      \"method\": \"Wnt inhibitor treatment of urogenital sinus explants, TCF/Lef:H2B-GFP transgenic reporter mice, Nkx3.1 null neonatal prostates\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic reporter mice plus pharmacological inhibition, single lab\",\n      \"pmids\": [\"23813564\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NKX3.1 is an androgen-regulated prostate-specific homeodomain transcription factor and haploinsufficient tumor suppressor that binds a TAAGTA consensus sequence to repress or activate target genes (including IGFBP-3, TWIST1, RAMP1, VEGF-C); it maintains prostate differentiation by interacting with G9a histone methyltransferase to activate UTY/KDM6c; suppresses prostate cancer initiation by protecting mitochondrial function (via HSPA9-mediated mitochondrial import and regulation of ETC gene transcription) and enhancing DNA damage repair (by activating ATM kinase, facilitating ATM and γH2AX recruitment, activating topoisomerase I, and promoting homology-directed repair to suppress TMPRSS2-ERG rearrangements); its protein stability is tightly controlled by a network of post-translational modifications including stabilizing phosphorylation by CK2 (Thr89/Thr93) and Pim-1, destabilizing phosphorylation by DYRK1B (Ser185) and LIMK2, inflammatory cytokine-induced phosphorylation at Ser196 leading to ubiquitination by TOPORS and proteasomal degradation, and protection from degradation by nuclear PTEN (which dephosphorylates Ser185); NKX3.1 also cooperates with the AR-FoxA1 transcriptional network, opposes Myc transcriptional activity on shared target genes, and, in non-prostate contexts (T-ALL), is activated by the TAL1-LMO-Ldb1 complex to drive leukemic proliferation and, during iPSC reprogramming, functions downstream of IL-6-STAT3 to activate OCT4.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NKX3-1 is an androgen-regulated, prostate-specific homeodomain transcription factor that functions as a haploinsufficient tumor suppressor by maintaining epithelial differentiation, protecting against oxidative and genotoxic stress, and restraining oncogenic signaling. It binds a TAAGTA consensus sequence to repress targets such as TWIST1, RAMP1, and VEGF-C, and activates others including IGFBP-3, recruiting chromatin-modifying cofactors (HDAC1, p300/PCAF, G9a) to regulate histone acetylation and methylation at target loci [PMID:10871372, PMID:17602165, PMID:27339988, PMID:19258508]. NKX3-1 enhances DNA damage repair by activating ATM kinase and topoisomerase I, promoting homology-directed repair that suppresses TMPRSS2-ERG rearrangements, and protects mitochondrial function through HSPA9-mediated mitochondrial import and regulation of electron transport chain gene transcription [PMID:23890999, PMID:17234752, PMID:25977336, PMID:33893149]. Its protein stability is tightly controlled by stabilizing phosphorylation (CK2 at Thr89/Thr93; Pim-1) and destabilizing phosphorylation (DYRK1B at Ser185; LIMK2), with inflammatory cytokine-induced Ser196 phosphorylation triggering TOPORS-mediated ubiquitination, while nuclear PTEN opposes degradation by dephosphorylating Ser185 [PMID:16581776, PMID:25777618, PMID:18757402, PMID:31213464].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing NKX3-1 as a prostate-specific, androgen-regulated homeoprotein answered what tissue and hormonal context governs its expression, framing all subsequent functional studies.\",\n      \"evidence\": \"RNase protection, in situ hybridization, castration, and androgen-stimulation experiments in mouse prostate and LNCaP cells\",\n      \"pmids\": [\"9142502\", \"9537602\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cis-regulatory elements mediating androgen regulation not mapped\", \"Protein-level regulation not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Targeted disruption showing prostatic hyperplasia and dysplasia even in heterozygotes established NKX3-1 as a haploinsufficient tumor suppressor, resolving its loss-of-function phenotype.\",\n      \"evidence\": \"Nkx3.1 knockout mice with histopathology and tissue recombinants\",\n      \"pmids\": [\"10215624\", \"11002344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets mediating growth suppression unknown\", \"Whether loss alone drives cancer or requires cooperating events\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of the TAAGTA consensus binding site and demonstration of transcriptional repression defined NKX3-1's DNA-binding specificity and mode of transcriptional action.\",\n      \"evidence\": \"Binding site selection, EMSA, and luciferase reporter assays\",\n      \"pmids\": [\"10871372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide binding sites not mapped\", \"Cofactors mediating repression unidentified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic cooperativity between Nkx3.1 and Pten loss, mediated by synergistic Akt activation, placed NKX3-1 within the PI3K-AKT tumor suppression pathway.\",\n      \"evidence\": \"Compound mutant mice with phospho-Akt Western blot and histopathology\",\n      \"pmids\": [\"11854455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NKX3-1 directly modulates PTEN expression or signaling not resolved\", \"Downstream Akt effectors responsible for cooperativity unidentified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstration that Nkx3.1 loss deregulates oxidative stress enzymes and increases 8-OHdG revealed a protective role against oxidative DNA damage, a key early cancer-promoting event.\",\n      \"evidence\": \"Gene expression profiling and 8-OHdG immunohistochemistry in Nkx3.1 null and compound mutant mice\",\n      \"pmids\": [\"16061659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect transcriptional control of antioxidant genes not distinguished\", \"Functional rescue by restoring individual target genes not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Multiple studies in 2006 defined NKX3-1's cofactor interactions and post-translational regulation: CK2α′ phosphorylation at Thr89/Thr93 stabilizes the protein; NKX3-1 associates with HDAC1 to increase p53 acetylation; and structural analysis of a hereditary mutation (T164A) demonstrated homeodomain destabilization.\",\n      \"evidence\": \"In vitro kinase assays with MS, Co-IP for HDAC1, NMR spectroscopy of T164A mutant homeodomain, functional rescue in Pten-null mice\",\n      \"pmids\": [\"16581776\", \"16697957\", \"16397218\", \"16201967\", \"16814806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase responsible for destabilizing Ser185 phosphorylation not yet known\", \"How HDAC1 sequestration by NKX3-1 mechanistically increases p53 acetylation not fully resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that NKX3-1 directly binds and activates topoisomerase I, and recruits p300/PCAF for histone acetylation at dosage-sensitive loci, provided the first enzymatic and chromatin-remodeling partners explaining its DNA-damage and transcriptional functions.\",\n      \"evidence\": \"Affinity pulldown, co-IP, in vitro Topo I activity assays, ChIP for histone acetylation, HDAC inhibitor rescue\",\n      \"pmids\": [\"17234752\", \"17602165\", \"18077445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Topo I activation and chromatin remodeling are functionally linked\", \"Structural basis of NKX3-1–Topo I interaction unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapping the inflammation-triggered degradation pathway—TNF-α-induced Ser196 phosphorylation leading to TOPORS-mediated ubiquitination—explained how inflammation accelerates NKX3-1 loss in prostate cancer.\",\n      \"evidence\": \"Site-directed mutagenesis (S196A, S185A), cytokine treatment, ubiquitination and half-life assays\",\n      \"pmids\": [\"18757402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for Ser196 phosphorylation not identified\", \"In vivo inflammation model not used\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of IGFBP-3 as a transcriptional target that mediates NKX3-1's attenuation of IGF-I/PI3K/AKT signaling connected NKX3-1 tumor suppression to a defined growth factor signaling axis.\",\n      \"evidence\": \"Microarray, stable transfection, siRNA knockdown of IGFBP-3, Western blot for IGF pathway phosphorylation\",\n      \"pmids\": [\"19258508\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding of NKX3-1 to IGFBP-3 regulatory elements not shown by ChIP at the time\", \"Contribution of IGFBP-3 versus other targets to in vivo tumor suppression not separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"NKX3-1 was shown to localize to DNA damage sites and activate ATM kinase autophosphorylation, establishing a direct mechanistic role in the DNA damage response beyond Topo I activation; concurrently, genome-wide ChIP-seq revealed extensive co-occupancy with AR and FoxA1.\",\n      \"evidence\": \"Immunofluorescence co-localization, ATM kinase assays, siRNA/overexpression, ChIP-seq in LNCaP cells\",\n      \"pmids\": [\"20395202\", \"22083957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ATM–NKX3-1 physical interaction not yet mapped to specific domains\", \"How co-occupancy with AR/FoxA1 is mechanistically organized at enhancers\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"In T-ALL, NKX3-1 was identified as a direct target of the TAL1-LMO-Ldb1 oncogenic complex, revealing a non-prostate proliferative function where NKX3-1 promotes leukemic growth via miR-17-92.\",\n      \"evidence\": \"ChIP at NKX3-1 promoter, siRNA/shRNA knockdown, in vivo leukemia engraftment\",\n      \"pmids\": [\"20855495\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Targets of NKX3-1 besides miR-17-92 in T-ALL not characterized\", \"Whether NKX3-1 functions as tumor suppressor or oncogene is context-dependent and not reconciled\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A cluster of studies refined the DNA-damage mechanism: NKX3-1 Tyr222 phosphorylation upon damage enables direct ATM binding and DNA-damage-independent ATM activation; NKX3-1 also modulates Topo I by inhibiting its resolvase activity while enhancing full-length enzyme activity; and NKX3-1 binds the ERG breakpoint to suppress TMPRSS2-ERG rearrangements by favoring homology-directed repair.\",\n      \"evidence\": \"Co-IP with phospho-mutants, in vitro ATM kinase assay, reconstituted Topo I domain assays, ChIP at ERG breakpoint, FISH for loci juxtaposition\",\n      \"pmids\": [\"23890999\", \"23557481\", \"25977336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for Tyr222 phosphorylation not identified\", \"Structural basis of NKX3-1–ATM interaction unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Pim-1 kinase was identified as a stabilizer of NKX3-1, phosphorylating multiple residues including Ser185, counteracting the destabilizing pathway and adding complexity to NKX3-1 turnover regulation.\",\n      \"evidence\": \"Mass spectrometry of phosphosites, Pim-1 inhibitor treatment, mutational analysis, protein half-life assays\",\n      \"pmids\": [\"23129228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Pim-1-mediated phosphorylation at the same site (Ser185) stabilizes while other kinases destabilize is not mechanistically reconciled\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"DYRK1B was identified as the kinase that phosphorylates NKX3-1 Ser185 to trigger steady-state degradation, resolving a long-standing question about the kinase mediating the constitutive turnover pathway.\",\n      \"evidence\": \"siRNA library screen, in vitro kinase assay, co-IP, protein half-life assay, DYRK1B inhibitors\",\n      \"pmids\": [\"25777618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DYRK1B inhibitors can stabilize NKX3-1 in vivo to suppress cancer not tested\", \"Interplay between DYRK1B, Pim-1, and CK2 at overlapping sites not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"NKX3-1 gain-of-function was shown to respecify seminal vesicle epithelium toward a prostate fate via interaction with the G9a histone methyltransferase and activation of UTY/KDM6c, establishing the chromatin mechanism underlying NKX3-1's role as a master regulator of prostate identity.\",\n      \"evidence\": \"In vivo renal graft respecification, Co-IP of NKX3-1–G9a, gene expression profiling, loss-of-function mice\",\n      \"pmids\": [\"27339988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide targets of the NKX3-1–G9a complex not mapped\", \"Whether G9a interaction is required for tumor suppression not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"NKX3-1 was shown to activate endogenous OCT4 downstream of IL-6–STAT3 signaling and substitute for OCT4 in iPSC reprogramming, revealing a previously unsuspected role in pluripotency circuits.\",\n      \"evidence\": \"Heterokaryon reprogramming, siRNA knockdown, STAT3 inhibition, iPSC generation from mouse and human fibroblasts\",\n      \"pmids\": [\"30013107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which NKX3-1 activates OCT4 transcription not defined\", \"Whether this function relates to prostate stem cell biology not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Nuclear PTEN was identified as a phosphatase that directly dephosphorylates NKX3-1 Ser185, opposing DYRK1B and stabilizing NKX3-1 protein; this explained why PTEN loss leads to rapid NKX3-1 protein decline and connected two major prostate tumor suppressors in a single post-translational circuit.\",\n      \"evidence\": \"Co-IP (PTEN–NKX3-1), nuclear localization mutants, protein half-life assay, gene-targeted mice\",\n      \"pmids\": [\"31213464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PTEN's phosphatase activity on NKX3-1 not reconstituted with purified components\", \"Whether lipid phosphatase and NKX3-1 phosphatase activities are coordinated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"NKX3-1 was shown to be imported into mitochondria via HSPA9 to regulate mitochondrial-encoded ETC gene transcription and restore oxidative phosphorylation, providing a mechanistic basis for its protection against oxidative stress and cancer initiation.\",\n      \"evidence\": \"Mitochondrial fractionation, HSPA9 Co-IP, mitochondrial transcription assay, genetically engineered mice, human organotypic cultures\",\n      \"pmids\": [\"33893149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a homeodomain protein binds mitochondrial DNA promoters is not structurally defined\", \"Relative contribution of mitochondrial versus nuclear functions to tumor suppression not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the NKX3-1–ATM and NKX3-1–mitochondrial DNA interactions, the kinase responsible for damage-induced Tyr222 phosphorylation, how the same Ser185 site mediates opposing stability outcomes depending on kinase context, whether pharmacological stabilization of NKX3-1 (via DYRK1B inhibitors) prevents cancer in vivo, and how NKX3-1's prostate-specific tumor-suppressive versus T-ALL-promoting activities are determined by cellular context.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NKX3-1–ATM interaction\", \"Kinase for Tyr222 phosphorylation unidentified\", \"In vivo therapeutic efficacy of NKX3-1 stabilization not tested\", \"Context-dependent oncogene vs tumor suppressor function not mechanistically resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 3, 12, 27, 28, 31]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 15, 19, 27, 28, 32, 40]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 14, 34]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 15, 21, 27, 32]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [20, 25, 26, 31]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [15, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 5, 6, 7, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 4, 32, 41]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AR\", \"ATM\", \"TOP1\", \"G9a\", \"HDAC1\", \"TOPORS\", \"PTEN\", \"DYRK1B\"],\n    \"other_free_text\": []\n  }\n}\n```"}